Lisata Therapeutics receives waiver for pediatric studies of certepetide in pancreatic cancer Lisata Therapeutics Inc (NASDAQ:LSTA) has received a Paediatric Investigation Plan (PIP) waiver from the European Medicines Agency (EMA) for its…
Lisata Therapeutics reports strong 1Q performance, cash to support operations into 2026 Lisata Therapeutics Inc (NASDAQ:LSTA) has ended its first quarter of 2024 with nearly $43.3 million in cash to fund its…